Emodin (37) also demonstrated in vitro and in vivo suppressive effects against anaplastic thyroid cancer by affecting TRAF6-mediated pathways. This evidence concerns the gene TRAF6 and thyroid gland undifferentiated (anaplastic) carcinoma.